Imagine finishing breast cancer surgery and facing a choice: weeks of daily radiation trips, or a newer, one-and-done approach. A recent study followed 148 women who chose the single-dose option, called stereotactic partial breast irradiation (S-PBI), delivered with a machine called the GammaPod. The goal was to see if this faster method could keep the cancer from coming back while being gentle on the body.
After about two years, the early results are encouraging. The cancer came back in the treated breast in a very small percentage of women. Side effects were mostly mild, with a small number of women developing some firmness (fibrosis) in the breast tissue. Importantly, no severe toxicities were reported, and the treatment was described as very well-tolerated.
It's crucial to remember this is a first, promising look. This was a phase 2 trial at a single hospital, without comparing the single dose directly to the standard multi-week regimen. The researchers themselves note that a randomized trial—the gold standard—is needed to truly know if this one-dose option is just as good at preventing cancer recurrence over the long term. For now, it offers a glimpse of a potentially more convenient future for breast cancer care.